Following the recent approval by the US Food and Drug Administration (FDA) of the Thoraflex Hybrid Frozen Elephant Trunk (FET) device for the treatment of patients with complex aortic arch disease, Terumo Aortic announced the first commercial implant of this device in the United States.
Thoraflex Hybrid is a single use medical device combining a Gelweave polyester graft with a Nitinol self-expanding stent graft. It is indicated for the open surgical repair or replacement of damaged or diseased vessels of the aortic arch and repair of the descending thoracic aorta with or without involvement of the ascending aorta, in cases of aneurysm and/or dissection.
The implant was performed by the Principal Investigator of the Thoraflex Hybrid Study, Joseph Coselli, MD, Professor, Executive Vice Chair, Division of Cardiothoracic Surgery, Baylor College of Medicine, Houston, Texas, US.
Joseph Coselli commented: “The procedure was very successful, the device performed well, and the patient is making a good recovery. Thoraflex Hybrid is the first of its kind device used in Frozen Elephant Trunk (FET) repair in the United States and it will allow US physicians to treat patients who may be at great risk of rupture with a device that brings the primary benefit of requiring a single stage procedure for those with suitably limited disease, instead of two procedures which has been the conventional pathway in the United States for this group of patients”.
Paul Kuznik, President of Terumo Aortic North America, said: “This commercial implant represents a significant milestone for the company and a tremendous opportunity for Terumo Aortic in the United States. This innovative hybrid device complements our open surgical graft and endovascular portfolio making us one of the strongest medical device companies within the aortic space, helping to deliver our commitment to provide solutions for every aorta.”
Thoraflex Hybrid received CE Mark approval in 2012 and FDA approval in 2022 with more than 13,000 devices sold commercially around the world over the past 10 years. This device is integral to Terumo Aortic’s market-leading portfolio of surgical, endovascular and hybrid devices to treat every segment of the aorta.
RELATED: JustLight launches clinical trials of Sunflower Rx for Alzheimer’s disease
About Terumo Aortic
At Terumo Aortic, we partner with our customers to revolutionise aortic care. We deliver innovation, versatility and precision with the broadest range of solutions that can be personalised for every patient. We are further complementing our implantable device portfolio through the development of digital technologies.
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.
